Pediatrix Medical Group (NYSE:MD) Rating Increased to Buy at StockNews.com

Pediatrix Medical Group (NYSE:MD) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Wednesday.

MD has been the topic of several other reports. Mizuho lifted their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Jefferies Financial Group lifted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. UBS Group lifted their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Finally, Macquarie began coverage on Pediatrix Medical Group in a research report on Monday, December 16th. They issued an “outperform” rating and a $18.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $16.25.

Pediatrix Medical Group Trading Up 1.2 %

NYSE MD opened at $14.01 on Wednesday. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -4.58, a price-to-earnings-growth ratio of 1.40 and a beta of 1.58. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41. The business’s fifty day moving average is $14.03 and its 200 day moving average is $11.95. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.29 EPS. As a group, sell-side analysts expect that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insider Activity at Pediatrix Medical Group

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. The trade was a 5.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares of the company’s stock, valued at $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MD. Quest Partners LLC increased its holdings in Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares in the last quarter. Quarry LP boosted its stake in shares of Pediatrix Medical Group by 54.1% in the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock worth $55,000 after buying an additional 1,662 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Pediatrix Medical Group in the 2nd quarter worth approximately $72,000. CWM LLC boosted its stake in shares of Pediatrix Medical Group by 134.0% in the 3rd quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after buying an additional 3,681 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in shares of Pediatrix Medical Group in the 2nd quarter worth approximately $81,000. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.